Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

42551 reported adverse events

Drugs of this class: LAMIVUDINE LAMIVUDINE AND ZIDOVUDINE ABACAVIR AND LAMIVUDINE EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE ENTECAVIR LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE ABACAVIR , LAMIVUDINE AND ZIDOVUDINE ABACAVIR SULFATE AND LAMIVUDINE ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE ABACAVIR SULFATE, LAMIVUDINE, AND ZIDOVUDINE DOLUTEGRAVIR SODIUM AND LAMIVUDINE DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

These side effects are most commonly reported by patients taking drugs of the Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

# Side effect Count
0 FOETAL EXPOSURE DURING PREGNANCY 2546
1 DRUG RESISTANCE 1946
2 DRUG EXPOSURE DURING PREGNANCY 1879
3 PYREXIA 1769
4 DRUG INTERACTION 1663
5 VIROLOGIC FAILURE 1502
6 NAUSEA 1495
7 PAIN 1483
8 ANAEMIA 1469
9 DIARRHOEA 1318
See all common reactions for Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PINEALOBLASTOMA 76 0.8444
1 PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA 87 0.8208
2 GENOTYPE DRUG RESISTANCE TEST 39 0.8125
3 CSF HIV ESCAPE SYNDROME 74 0.6271
4 VIRAL MUTATION IDENTIFIED 1305 0.5676
5 IMMUNE RECONSTITUTION SYNDROME 686 0.5297
6 HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION 99 0.4829
7 AIDS ENCEPHALOPATHY 26 0.4483
8 VIROLOGIC FAILURE 1502 0.4444
9 HIV-ASSOCIATED NEUROCOGNITIVE DISORDER 29 0.4028
See all enriched reactions for Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]